DSKYF (Daiichinkyo Co) FFO


DSKYF Daiichi Sankyo Co Ltd DSKYF
73 GF Score
Price $14.76
GF Value $37.40
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Daiichinkyo Co FFO?

FFO (Funds from operations) only applies to REITs.

DSKYF
73GF Score
Daiichi Sankyo Co Ltd DSKYF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Daiichinkyo Co (DSKYF) Overvalued in 2026?

Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued. The current stock price of $14.76 is trading 60.5% below its estimated GF Value™ of $37.40. GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.

Key valuation signals for DSKYF:

  • FFO:
  • GF Value™: $37.40 vs. price of $14.76 (60.5% below fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the DSKYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Daiichinkyo Co Business Description

Address 3-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
73GF Score

Get the complete analysis for DSKYF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.76
Price
$37.40
GF Value